Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery

References

• Arcelus JI, Monreal M, Caprini JA et al.; the RIETE Investigators. Clinical presentation and time-course of postoperative venous thromboembolism: results from the RIETE Registry. Thromb. Haemost.99(3), 546–551 (2008).
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Prins MR. Long-term outcomes after deep venous thrombosis of the lower extremities. Vasc. Med.3(1), 57–60 (1998).
   PubMedGoogle Scholar
• Tapson VF, Hyers TM, Waldo AL et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch. Intern. Med.165, 1458–1464 (2005).
   PubMed Web of Science ®Google Scholar
• Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest133, 381S–453S (2008).
   PubMed Web of Science ®Google Scholar
• O’Donnell M, Linkins LA, Kearon C et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch. Intern. Med.163(11), 1362–1366 (2003).
   PubMedGoogle Scholar
• Anderson FA Jr, Hirsh J, White K et al. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee Registry. Chest124, 349S–356S (2003).
   PubMed Web of Science ®Google Scholar
• Stassen JM, Hauel NH, Nar H et al. Identification and in vitro characterization of BIBR 953 ZW, a novel synthetic low molecular weight direct thrombin inhibitor. Presented at: The 28th Congress of the International Society on Thrombosis and Haemostasis. Paris, France, 6–12 July 2001.
   Google Scholar
• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin. Pharmacokinet.47(5), 285–295 (2008).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N et al.; the RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost.5(11), 2178–2185 (2007).
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Davidson BL, Comp PC et al. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty24(1), 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N et al.; the RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet370(9591), 949–956 (2007).
   PubMed Web of Science ®Google Scholar
• Eriksson B, Dahl OE, Kurth AA et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial. Presented at: 21st International Congress on Thrombosis. Milan, Italy, 6–9 July 2010.
   Google Scholar
• Huo M, Eriksson B, Dahl O et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary hip arthroplasty: the RE-NOVATE II randomized trial. Presented at: 15th Congress of the European Hematology Association. Barcelona, Spain, 10–13 June 2010.
   Google Scholar
• Bellamy L, Rosencher N, Eriksson BI. Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate. Patient Prefer. Adherence3, 173–177 (2009).
   PubMed Web of Science ®Google Scholar
• Wilke T. Patient preferences for an oral anticoagulant after major orthopedic surgery. Results of a German Survey. Patient2(1), 39–49 (2009).
   PubMedGoogle Scholar
• Schulman S, Kearon C, Kakkar AK et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med.361(24), 2342–2352 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.361, 1–13 (2009).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N et al.; the RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost.5(11), 2178–2185 (2007).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N et al.; the RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet370(9591), 949–956 (2007).
   PubMed Web of Science ®Google Scholar
• Friedman RJ, Dahl OE, Rosencher N et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb. Res.126(3), 175–182 (2010).
   PubMed Web of Science ®Google Scholar
• Wolowacz SE, Roskell NS, Plumb JM et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis. Thromb. Haemost.101(1), 77–85 (2009).
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br. J. Clin. Pharmacol.64, 292–303 (2007).
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos.36, 386–399 (2008).
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Reilly P, Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am. J. Cardiol.100, 1419–1426 (2007).
   PubMed Web of Science ®Google Scholar
• Busby LT, Weyman A, Rodgers GM. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am. J. Hematol.67, 54–56 (2001).
   PubMed Web of Science ®Google Scholar
• Thorevska N, Amoateng-Adjepong Y, Sabahi R et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest125, 856–863 (2004).
   PubMed Web of Science ®Google Scholar
• Dahl OE, Kurth AA, Rosencher N et al. Efficacy and safety profile of dabigatran etexilate for the prevention of venous thromboembolism in moderately renally impaired patients after total knee or hip replacement surgery. Blood112(11), 361 (2008) (Abstract 981).
   Google Scholar
• Dahl OE, Kurth AA, Rosencher N et al. Efficacy and safety profile of dabigatran etexilate compared with enoxaparin in primary venous thromboembolism prevention after total knee or hip replacement surgery in patients over 75 years. Blood112(11), 167 (2008) (Abstract 437).
   Google Scholar
• Fuji T, Fuijita S, Ujihira T et al. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients, with a safety profile comparable to placebo. J. Arthroplasty25(8), 1267–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Ivanovic N, Beinema M, Brouwers JR et al. Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban (brief record). Expert Rev. Pharmacoeconomics Outcomes Res.7, 49–58 (2007).
   PubMedGoogle Scholar
• Martins HS, Scalabrini-Neto A, Velasco IT. Dabigatran versus enoxaparin after total hip replacement. Lancet370(9604), 2002–2003 (2007).
   PubMed Web of Science ®Google Scholar
• Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health Technol. Assess.13(Suppl 2), 55–62 (2009).
   PubMed Web of Science ®Google Scholar
• Wolowacz SE, Roskell NS, Maciver F et al. Economic analysis of dabigatran etexilate for the prevention of venous thromboembolism following total knee and hip replacement surgery. Clin. Ther.31(1), 1–19 (2009).
   PubMed Web of Science ®Google Scholar
• Bouee S, Zufferey P, Fagnani F. Budget impact analysis of Pradaxa thromboprophylaxis after total hip or total knee replacement. Therapie64(4), 249–257 (2009).
   PubMed Web of Science ®Google Scholar
• Wilke T, Neumann K, Klapper U et al. Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals. Orthopade37(5), 448–456 (2008).
   PubMed Web of Science ®Google Scholar
• McCullagh L, Tilson L, Walsh C, Barry M. A cost–effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics27(10), 829–846 (2009).
   PubMed Web of Science ®Google Scholar
• Boersma C, Kappelhoff BS, Postma MJ. Dabigatran etexilate is cost-saving for the primary prevention of venous thromboembolic events following major orthopaedic surgery in The Netherlands. Presented at: The 12th Annual European Congress of ISPOR. Paris, France, 24–27 October 2009.
   Google Scholar
• Boersma C, Kappelhoff BS, Postma MJ. Dabigatran etexilate is cost-saving for the primary prevention of venous thromboembolic events following major orthopaedic surgery in The Netherlands. Presented at: 51st Annual Meeting of the American Society of Hematology. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Wolowacz SE, Hess N, Brennan VK et al. Cost–effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years. Curr. Med. Res. Opin.24(10), 2993–3006 (2008).
   PubMed Web of Science ®Google Scholar
• Watts AC, Howie CR, Simpson AH. Assessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplasty. J. Bone Joint Surg. Br.88-B, 107–110 (2006).
   Google Scholar
• Botteman MF, Caprini J, Stephens JM et al. Results of an economic model to assess the cost–effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin. Ther.24(11), 1960–1986 (2002).
   PubMed Web of Science ®Google Scholar
• Ingelgard A, Hedner E, Stigendal J et al. Patient-reported outcomes in patients with deep vein thrombosis treated with warfarin. Presented at: 17th International Congress on Thrombosis. Bologna, Italy, 26–30 October 2002.
   Google Scholar
• Robinson A, Thomson R, Parkin D et al. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J. Health Serv. Res. Policy6(2), 92–98 (2001).
   PubMedGoogle Scholar
• NICE. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. Technology appraisal guidance 157. National Institute for Health and Clinical Excellence, London, UK (2008).
   Google Scholar
• Scottish Medicines Consortium. Drug Advice: Dabigatran Etexilate, 75 mg and 110 mg Hard Capsules (Pradaxa). Scottish Medicines Consortium, Glasgow, Scotland (2008).
   Google Scholar
• Wolowacz SE, Roskell NS, Plumb JM et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb. Haemost.103(2), 360–371 (2009).
   PubMed Web of Science ®Google Scholar
• Bradley-Kennedy C, Wolowacz SE, Roskell NS, Plumb JM. Cost–effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism (VTE) in patients undergoing total hip replacement surgery (THR). Presented at: 22nd International Congress of the International Society on Thrombosis and Haemostasis. Boston, MA, USA, 11–16 July 2009.
   Google Scholar
• Bradley-Kennedy C, Wolowacz SE, Roskell NS, Plumb JM. Cost–effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement surgery (TKR). Presented at: 22nd International Congress of the International Society on Thrombosis and Haemostasis. Boston, MA, USA, 11–16 July 2009.
   Google Scholar
• Canadian Joint Replacement Registry. 2007 Annual Report – Hip and Knee Replacements in Canada. Canadian Institute for Health Information, Ottawa, Canada (2008).
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada (3rd Edition). Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada (2006).
   Google Scholar
• Skedgel C, Goeree R, Pleasance S et al. The cost–effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J. Bone Joint Surg. Am.89, 819–828 (2007).
   PubMed Web of Science ®Google Scholar
• Bradley-Kennedy C, Wolowacz SE, Roskell NS, Clemens A. Cost–effectiveness of dabigatran etexilate 150 mg in Canada for the prevention of venous thromboembolism in patients undergoing total knee or hip arthroplasty that have moderate impairment of renal function. Presented at: 22nd International Congress of the International Society on Thrombosis and Haemostasis. Boston, MA, USA, 11–16 July 2009.
   Google Scholar
• González-Rojas N, Vieta A, Wolowacz SE. Economic analysis of dabigatran etexilate for the primary prevention of venous thromboembolism in patients undergoing total hip or knee replacement surgery (Spain). Pharmacoeconomics6(4), 126–145 (2009).
   Google Scholar
• González-Rojas N, Vieta A, Monreal M, Wolowacz SE. Economic analysis of dabigatran etexilate for the primary prevention of venous thromboembolism following total hip or knee replacement in Spain. Presented at: 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Paris, France, 24–27 October 2009.
   Google Scholar
• González-Rojas N, Monreal M, Wolowacz SE. Economic evaluation of dabigatran etexilate for the primary prevention of venous thromboembolism after total knee and hip replacement surgery. Presented at: Spanish Society of Hospital Pharmacists. Zaragoza, Spain, 22–25 September 2009.
   Google Scholar
• Mateus C, Wolowacz S, Pereira J. Cost–effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in total hip and knee replacement in Portugal. Presented at: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Orlando, FL, USA, 16–20 May 2009.
   Google Scholar
• Sutton A, Ades AE, Cooper N et al. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics26(9), 753–767 (2008).
   PubMed Web of Science ®Google Scholar
• Song F, Altman DG, Glenny AM et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br. Med. J.326(7387), 472–475 (2003).
   PubMed Web of Science ®Google Scholar
• Plumb JM, Clemens A, Monz BU. Cost–effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics28(9), 781–782; author reply 782–784, 784–785 (2010).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost.5(12), 2368–2375 (2007).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med.361(6), 594–604 (2009).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet375(9717), 807–815 (2010).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Davidson BL et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb. Haemost.101(1), 68–76 (2009).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Turpie AG, Lassen MR et al.; ONYX-2 Study Group. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J. Thromb. Haemost.8(4), 714–721 (2010).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Buller HR et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost.3, 103–111 (2005).
   PubMed Web of Science ®Google Scholar
• Wolowacz S, Roskell N, Maciver F et al. Cost–effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in patients undergoing total hip or total knee replacement surgery. Presented at: 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Athens, Greece, 8–11 November 2008.
   Google Scholar
• Wolowacz SE, Roskell NS, Plumb JM et al. Cost–effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in elderly patients undergoing total hip or knee arthroplasty. Presented at: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Orlando, FL, USA, 16–20 May 2009.
   Google Scholar
• Wolowacz SE, Roskell NS, Plumb JM et al. Cost–effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty that have moderate impairment of renal function. Presented at: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Orlando, FL, USA, 16–20 May 2009.
   Google Scholar